Company Overview and News

0
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities 6-K (Current Report of Foreign Issuer)

2018-08-02 sec.gov
6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
IND

0
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities 6-K (Current Report of Foreign Issuer)

2018-08-02 sec.gov
6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
IND

12
Your Daily Pharma Scoop: Biohaven In Pivotal Stage, Merck Trial Positive, FDA Waives EyeGate

2018-07-27 seekingalpha
Discussion: Biohaven Pharmaceutical Holding Company (BHVN) commences Phase 2/3 trial of its candidate BHV-4157 (trigriluzole) in patients with mild-to-moderate Alzheimer's disease (‘AD). Patient enrollment is expected to begin shortly. Following details of the study plan have been shared by the company. During the 48-week trial period, the 292-subject study will be randomized between trigriluzole and placebo.
EYEG GILD IMROY IMRN AGRX LLY EYEGW IND BHVN SLS ALDX BGNE ABBV RDUS APLS SNNA

0
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities FORM 6-K (Current Report of Foreign Issuer)

2018-07-02 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCH
IND

10
InflaRx: Buy The Dip

2018-06-29 seekingalpha
Management is executing on their gameplan via exploring the potential of IFX-1 in additional indications, starting with a phase 2 study in patients with ANCA-associated vasculitis (AAV).
CCXI IND

0
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities FORM 6-K (Current Report of Foreign Issuer)

2018-06-25 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCH
IND

0
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities FORM 11-K

2018-06-22 sec.gov
Form 11-K Table of Contents UNITED STATES
IND

0
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities FORM 6-K (Current Report of Foreign Issuer)

2018-06-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
IND

0
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities FORM 6-K (Current Report of Foreign Issuer)

2018-06-04 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCH
IND

10
Crispr Stock Tumbles On FDA Clinical Hold, But European Study Remains On Track

2018-06-04 seekingalpha
Crispr Therapeutics received a clinical hold from the FDA for an IND on CTX-001 in treating patients with sickle cell disease.
SCD VRTX CRSP IND

0
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities null

2018-05-31 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P-R P(&]B:@T\/"],:6YE87)I>F5D(#$O3" Q M,3%LQ,#<@ M,S)=+TEN9F\@,3 V(# @4B],[email protected]@.#,O4')E=B Q,[email protected],3,Y+U1Y<&4O6%)E9B][email protected],R Q73X^
IND

0
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities null

2018-05-31 sec.gov
CORRESP Ms. Stephanie L. Sullivan Senior Technical and Policy Advisor Office of Financial Services Securities and Exchange Commission
IND

0
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities null

2018-05-31 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$R-R P(&]B:@T\/"],:6YE87)I>F5D(#$O3" Q M,3DV-#DO3R Q,CDO12 R,S8Q-"].(#,O5" Q,3DS,#$O2"!;(#0X," R,C5= M/CX-96YD;V)J#2 @(" @(" @(" @(" @#0HQ-# @,"!O8FH-/#PO1&5C;V1E M4&%R;7,\/"]#;VQU;6YS(#0O4')E9&EC=&]R(#$R/CXO1FEL=&5R+T9L871E M1&5C;V1E+TE$6SPW,C=!03DU131&,S%LQ,C<@ M,C1=+TEN9F\@,3(V(# @4B],[email protected]@-S$O4')E=B Q,3DS,#(O4F]O=" Q M,[email protected]@,"!2+U-I>[email protected],34Q+U1Y<&4O6%)E9B][email protected],B Q73X^
IND

0
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities null

2018-05-31 sec.gov
CORRESP Ms. Stephanie L. Sullivan Senior Technical and Policy Advisor Office of Financial Services Securities and Exchange Commission
IND

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 456837202